# Weekly Breakthroughs in Alzheimer’s Care

Newsy: Alzheimer’s News Weekly
Published: 2025-10-05T18:13:00.221Z
Source: https://newsyai.com/edition/91f39889-591b-4ebc-8538-7f625e90d198
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# The Alzheimer’s Treatment Briefing
Weekly roundup of the most important developments in Alzheimer’s care and research
Coverage period: September 29–October 5, 2025

---

## Top 5 stories (ranked)

1) Leqembi’s at‑home auto‑injector arrives in the U.S. on October 6
- What’s new
  - The FDA cleared a weekly, under‑the‑skin, at‑home version of lecanemab (brand name: Leqembi IQLIK) on August 29. Eisai and Biogen say it will be available to U.S. patients starting Monday, October 6, at a list price of $19,500/year for maintenance dosing after the initial 18‑month IV course. [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/), [TIME](https://time.com/7314266/alzheimers-drug-injectable-leqembi/)
- Why this matters
  - Easier access: Self‑injection at home cuts clinic time and may broaden access for people far from infusion centers or with mobility limits. 
  - System capacity: Fewer infusion visits can free up chairs for new starts.
  - Same goal, new format: It’s a different way to keep brain “amyloid” down after the initial IV phase; safety monitoring still matters, especially brain MRI checks early on.
  - Cost: List price is higher than IV maintenance, but Medicare caps many patients’ annual out‑of‑pocket costs; check plan specifics.
  - > Bottom line: For eligible early‑stage patients already through the IV start‑up, this is a practical step that could bring disease‑slowing therapy to more people. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai))

2) Street skepticism on weight‑loss/diabetes drugs for Alzheimer’s ahead of readouts
- What’s new
  - Morgan Stanley downgraded Novo Nordisk this week, citing a 75% chance that its semaglutide Alzheimer’s trial will miss its goal. The note also raises pressure concerns (e.g., U.S. pricing, competition) around the GLP‑1 class. [MarketWatch](https://www.marketwatch.com/story/morgan-stanley-expects-novo-nordisk-alzheimer-trial-to-fail-as-it-slashes-rating-98a9eeee)
- Why this matters
  - Keep expectations realistic: GLP‑1s (like Ozempic/Wegovy) are promising for diabetes and weight loss, but whether they slow Alzheimer’s remains unproven in randomized trials.
  - Research continues: Multiple trials are running; outcomes will guide whether metabolic therapies have a role in brain protection.
  - > Bottom line: Don’t count on GLP‑1s for cognitive benefit yet; the next year of trial readouts will be decisive. ([marketwatch.com](https://www.marketwatch.com/story/morgan-stanley-expects-novo-nordisk-alzheimer-trial-to-fail-as-it-slashes-rating-98a9eeee?utm_source=openai))

3) What Monday’s Leqembi IQLIK launch means for care teams (and families)
- What’s new
  - With the at‑home injector rolling out October 6, clinics will start transitioning eligible patients from IV to weekly self‑injections after 18 months. [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/)
- Why this matters
  - Practical prep: Teams should confirm MRI schedules, ApoE status–based risk counseling, and training for safe home injections.
  - Candidate profile: Early symptomatic patients who’ve completed the IV “de‑plaque” phase and are tolerating therapy.
  - > Bottom line: Expect more flexible maintenance therapy but unchanged need for safety checks and shared decision‑making. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai))

4) Coming soon: Head‑to‑head access battle—monthly IV vs weekly at‑home
- What’s new
  - Leqembi now has two maintenance routes (monthly IV or weekly at‑home SC); Lilly’s Kisunla remains IV with a “stop‑when‑clear” approach. Payers and clinics will shape which path grows fastest. [TIME](https://time.com/7314266/alzheimers-drug-injectable-leqembi/)
- Why this matters
  - Personal fit: Some will prefer home convenience; others may choose monthly IV to avoid weekly injections.
  - Health equity: Home options can help rural patients—if MRI access and nurse support are in place.
  - > Bottom line: Choice of route could improve adherence and reach—key for real‑world benefit. ([time.com](https://time.com/7314266/alzheimers-drug-injectable-leqembi/?utm_source=openai))

5) Big‑picture context: Prevention momentum is building, but not “there” yet
- What’s new
  - Earlier this year, a long‑followed prevention cohort with inherited early‑onset risk showed that years‑long plaque‑removing therapy cut the chance of developing symptoms roughly in half; those participants are now continuing on another antibody. While not a new study this week, it frames why maintaining low amyloid matters for today’s maintenance strategies. [ALZFORUM summary](https://www.alzforum.org/news/research-news/plaque-removal-delays-onset-familial-alzheimers-disease)
- Why this matters
  - Rationale for maintenance: If keeping plaques down delays symptoms in ultra‑high‑risk people, staying on a maintenance dose after the IV phase makes clinical sense while we await broader prevention trial data.
  - > Bottom line: Today’s news about at‑home maintenance fits a longer trend: sustained plaque control may be key—pending confirmation in larger, more typical populations. ([alzforum.org](https://www.alzforum.org/news/research-news/plaque-removal-delays-onset-familial-alzheimers-disease?utm_source=openai))

---

## Quick takes (also this week)

- Access watch: Expect announcements from health systems and payers in the coming days about how they’ll handle training, MRI logistics, and copays for the new at‑home Leqembi format. Practical implementation will determine real‑world uptake. [Reuters background on launch timing/pricing](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai))

- Hype vs. hope on GLP‑1s: Despite observational hints that diabetes drugs could lower dementia risk, this week’s analyst note is a reminder that only randomized, Alzheimer’s‑specific trials can settle efficacy. [MarketWatch](https://www.marketwatch.com/story/morgan-stanley-expects-novo-nordisk-alzheimer-trial-to-fail-as-it-slashes-rating-98a9eeee). ([marketwatch.com](https://www.marketwatch.com/story/morgan-stanley-expects-novo-nordisk-alzheimer-trial-to-fail-as-it-slashes-rating-98a9eeee?utm_source=openai))

---

## What this means for patients and caregivers (plain language)

- Disease‑slowing drugs exist for people in the earliest stage of Alzheimer’s. The big change this week is practical: one of those drugs (Leqembi) is getting easier to take at home after you finish the initial IV phase.
- Safety still matters. Even with at‑home injections, you’ll need MRI checks and close communication with your care team, especially in the first months.
- New drug classes (like weight‑loss/diabetes medicines) are being tested, but we don’t have proof yet that they slow memory decline in Alzheimer’s.

---

## FAQs

- Who might be eligible for at‑home Leqembi injections?
  - People already diagnosed with early Alzheimer’s who completed 18 months of IV Leqembi and are doing well on it. Your clinician will confirm eligibility and monitoring plans. [TIME explainer](https://time.com/7314266/alzheimers-drug-injectable-leqembi/). ([time.com](https://time.com/7314266/alzheimers-drug-injectable-leqembi/?utm_source=openai))

- Is the at‑home version safer?
  - Side‑effect risks (like brain swelling/ARIA) are generally similar. The difference is convenience, not a free pass on monitoring. [Reuters overview](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai))

---

## Editor’s note on this week’s news flow
We tracked regulatory, payer, and industry updates daily. The most concrete, treatment‑relevant development for the week ending October 5, 2025 is the October 6 U.S. launch of at‑home Leqembi maintenance dosing. No major peer‑reviewed, practice‑changing Alzheimer’s treatment trials were published during the last seven days. If you want us to monitor a particular therapy (e.g., GLP‑1s, anti‑tau drugs), tell us and we’ll tailor the watchlist.
